Maravai LifeSciences Inc., a global provider of life science reagents and services to researchers and biotech innovators, has signed an agreement to acquire the DNA and RNA business of Officinae Bio.
 
The acquisition is expected to expand Maravai and TriLink BioTechnologies’ ability to assist customers in developing innovative nucleic acid-based therapies.
 
Officinae Bio, based in Venice, Italy, is a private technology company with a digital platform for designing therapeutics. This technology allows rapid mRNA prototyping to test various CAP analogs, chemical modifications, and sequence designs for client projects. Officinae Bio’s technology and services will enhance Maravai’s nucleic acid production, offering customers substantial benefits in developing innovative therapies for patients in need.
 
“Officinae Bio’s unique approach to sequence design brings a cutting-edge advantage to our Nucleic Acid Production business,” said Trey Martin, CEO of Maravai LifeSciences. “Its founder-led, experienced team maintains a dedicated focus on leveraging AI to help scale the organization and accelerate innovation. We are excited to welcome their exceptionally talented team to Maravai to help drive process and manufacturing innovation forward together.”
 
Davide De Lucrezia, CEO and co-founder of Officinae Bio, said, “I can think of no better team with which to unite than Maravai and TriLink, whose trusted quality and leadership supports our dedication to collaboration and continuous improvement in the life sciences. We remain committed to our current customers’ success and believe this transaction will further strengthen our ability to support their needs. This business combination will also allow us to strengthen our contribution to the GMP manufacturing of key enzymes needed for nucleic acid vaccine and therapeutic applications.”
 
The acquisition is subject to customary closing conditions and regulatory approvals and is expected to close early in 2025.

More Pharma Mergers & Acquisitions